Skip to main content
Taiga Nishihori, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

TaigaNishihoriMD

Oncology Tampa, FL

Hematologic Oncology

Physician

Overview of Dr. Nishihori

Dr. Taiga Nishihori, MD is an oncologist in Tampa, Florida. He is currently licensed to practice medicine in Florida and Connecticut. He is affiliated with H. Lee Moffitt Cancer Center and Research Institute.

Education & Training

  • Yale-New Haven Hospital
    Yale-New Haven HospitalFellowship, Medical Oncology, 2006 - 2009
  • Mount Sinai Beth Israel
    Mount Sinai Beth IsraelResidency, Internal Medicine, 2002 - 2006
  • Hokkaido University Faculty of Medicine
    Hokkaido University Faculty of MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2010 - 2022
  • CT State Medical License
    CT State Medical License 2006 - 2018
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Case Report Haploidentical Transplantation as a Promising Therapy for Relapsed Hemophagocytic Lymphohistiocytosis in an Older Adult Patient  
    Taiga Nishihori, Ernesto Ayala, ScienceDirect

Abstracts/Posters

  • Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
    Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
    Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
    Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval
    Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AvMed Health Open Access
    BCBS Blue Card PPO
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    BCBS Illinois PPO
    CIGNA Open Access
    CIGNA PPO
    Coventry Florida - Employer Group PPO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment